Modulation by progestogens of the effects of oestrogen on hepatic endocrine function in postmenopausal women

Summary objective  Oral but not transdermal oestrogen administration reduces IGF‐I, and increases GH binding protein (GHBP) reflecting effects on hepatic endocrine function in postmenopausal women. As progestogens attenuate the effects of oestrogen on circulating lipid levels according to their andr...

Full description

Saved in:
Bibliographic Details
Published in:Clinical endocrinology (Oxford) 2003-12, Vol.59 (6), p.690-698
Main Authors: Nugent, Ailish G., Leung, Kin-Chuen, Sullivan, David, Reutens, Anne T., Ho, Ken K. Y.
Format: Article
Language:English
Subjects:
Analysis of Variance
Biological and medical sciences
Carrier Proteins - blood
Cyproterone Acetate - therapeutic use
Dydrogesterone - therapeutic use
Endocrinopathies
Estradiol - therapeutic use
Estrogen Replacement Therapy
Estrogens, Conjugated (USP) - therapeutic use
Female
Fundamental and applied biological sciences. Psychology
Humans
Insulin-Like Growth Factor I - metabolism
Lipids - blood
Liver - drug effects
Liver - metabolism
Medical sciences
Medroxyprogesterone Acetate - therapeutic use
Middle Aged
Norethindrone - therapeutic use
Postmenopause - metabolism
Progestins - therapeutic use
Sex Hormone-Binding Globulin - analysis
Vertebrates: endocrinology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary objective  Oral but not transdermal oestrogen administration reduces IGF‐I, and increases GH binding protein (GHBP) reflecting effects on hepatic endocrine function in postmenopausal women. As progestogens attenuate the effects of oestrogen on circulating lipid levels according to their androgenic properties, we have investigated the impact of progestogen types on the hepatic endocrine effects of oestrogen. design  Four progestogens differing in androgenicity were co‐administered in a monthly cyclical regimen in random order to postmenopausal women receiving either oral (n = 9, premarin 1·25 mg) or transdermal (n = 10, Estraderm 100 µg patches twice weekly). The four progestogens were cyproterone acetate (CA 5 mg, antiandrogenic), dydrogesterone (20 mg, neutral), medroxyprogesterone acetate (MPA 10 mg, mildly androgenic), norethisterone (2·5 mg, androgenic). patients  Nineteen postmenopausal women (age 57 ± 3 years, mean ± SE) were studied. measurements  The effects of oestrogen alone and the combined effects with each progestogen type on IGF‐I, GHBP, SHBG, cholesterol, triglycerides and lipoprotein(a) were investigated. results  Mean IGF‐I fell while GHBP and SHBG levels increased with oral (P 
ISSN:0300-0664
1365-2265
DOI:10.1046/j.1365-2265.2003.01907.x